[1] Giralt S, Estey E, Albitar M,et al.Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.Blood. 1997;89(12):4531-4536.
[2] Slavin S, Nagler A, Naparstek E,et al.Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.Blood. 1998;91(3): 756-763.
[3] Childs R, Clave E, Contentin N,et al.Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses.Blood. 1999;94(9):3234-3241.
[4] Kottaridis PD, Milligan DW, Chopra R, et al.In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.Blood. 2000;96(7): 2419-2425.
[5] McSweeney PA, Niederwieser D, Shizuru JA,et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects.Blood. 2001;97(11): 3390-3400.
[6] Giralt S, Aleman A, Anagnostopoulos A, et al. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma.Bone Marrow Transplant. 2002;30(6):367-373.
[7] Mohty M, Jacot W, Faucher C,et al. Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen.Leukemia. 2003;17(11):2168-2177.
[8] Le Bourgeois A, Lestang E, Guillaume T,et al.Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT). Eur J Haematol. 2013r;90(3):177-186.
[9] Kharfan-Dabaja MA, Labopin M, Bazarbachi A,et al. Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT.Bone Marrow Transplant. 2014;49(9):1170-1175.
[10] Oudin C, Chevallier P, Furst S,et al.Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies.Haematologica. 2014;99(11):1762-1768.
[11] Confer DL.Unrelated marrow donor registries.Curr Opin Hematol. 1997;4(6):408-412.
[12] Sykes M, Preffer F, McAfee S,et al.Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation.Lancet. 1999;353(9166): 1755-1759.
[13] Ichinohe T, Uchiyama T, Shimazaki C,et al.Feasibility of HLA-haploidentical hematopoietic stem cell transplantation between noninherited maternal antigen (NIMA)-mismatched family members linked with long-term fetomaternal microchimerism.Blood. 2004;104(12):3821-3828.
[14] Raj K, Pagliuca A, Bradstock K,et al. Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning.Biol Blood Marrow Transplant. 2014;20(6):890-895.
[15] Cho BS, Yoon JH, Shin SH,et al.Comparison of allogeneic stem cell transplantation from familial-mismatched/haploidentical donors and from unrelated donors in adults with high-risk acute myelogenous leukemia. Biol Blood Marrow Transplant. 2012;18(10): 1552-1563.
[16] Lee KH, Lee JH, Lee JH,et al.Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced- intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.Biol Blood Marrow Transplant. 2009;15(1):61-72.
[17] Kurokawa T, Ishiyama K, Ozaki J,et al.Haploidentical hematopoietic stem cell transplantation to adults with hematologic malignancies: analysis of 66 cases at a single Japanese center.Int J Hematol. 2010;91(4):661-669.
[18] Symons HJ, Fuchs EJ.Hematopoietic SCT from partially HLA-mismatched (HLA-haploidentical) related donors.Bone Marrow Transplant. 2008;42(6):365-377.
[19] Tanaka J, Kanamori H, Nishiwaki S,et al.Reduced-intensity vs myeloablative conditioning allogeneic hematopoietic SCT for patients aged over 45 years with ALL in remission: a study from the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT).Bone Marrow Transplant. 2013;48(11):1389-1394.
[20] Koenecke C, Shaffer J, Alexander SI,et al.NK cell recovery, chimerism, function, and recognition in recipients of haploidentical hematopoietic cell transplantation following nonmyeloablative conditioning using a humanized anti-CD2 mAb, Medi-507.Exp Hematol. 2003;31(10):911-923.
[21] Ogawa H, Ikegame K, Yoshihara S,et al.Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.Biol Blood Marrow Transplant. 2006;12(10):1073-1084.
[22] Rizzieri DA, Koh LP, Long GD,et al.Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.J Clin Oncol. 2007; 25(6):690-697.
[23] Luznik L, O'Donnell PV, Symons HJ,et al.HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.Biol Blood Marrow Transplant. 2008;14(6):641-650.
[24] Burroughs LM, O'Donnell PV, Sandmaier BM,et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma.Biol Blood Marrow Transplant. 2008;14(11):1279-1287.
[25] Ikegame K, Yoshihara S, Taniguchi Y,et al.Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation.Exp Hematol. 2011;39(8):880-890. |